Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 35.9 percent decrease over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $32.013 million which beat the analyst consensus estimate of $31.443 million by 1.81 percent. This is a 37.76 percent increase over sales of $23.238 million the same period last year.